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Abstract 
Background: Medullary thyroid cancer (MTC) commonly presents with lymph node (LN) 
metastases, and has a worse prognosis than papillary thyroid cancer (PTC). Tumor size and 
LN involvement have been shown to affect stage of disease; however, to our knowledge, ours 
is the first study that attempts to correlate anterior neck pain on presentation with the extent 
of disease.  
Methods: We performed a retrospective review of patients with MTC who underwent an 
operation from February 1998 through December 2008. We compared the symptom of 
anterior neck pain with the pathologic extent of disease. Our control group comprised pa-
tients who underwent an operation for PTC. Analysis was performed using the Fisher’s exact 
test and the Mann-Whitney test. 
Results: Of the 109 patients with MTC, 50 (46%) met our inclusion criteria. Of the 50 pa-
tients with MTC, 11 presented with neck pain, compared to 3 of the 50 patients with PTC (p 
= 0.041). Of those 11 patients, 9 (82%) had LN involvement on final pathology, as compared 
with 14 (36%) of the 39 without neck pain (p = 0.014). Of patients with neck pain, 18% were 
diagnosed at stage I to II and 82% at stage III to IV, compared to 64% at stage I to II and 36% at 
stage III to IV (p = 0.014).  
Conclusions: Our study demonstrates that more patients with MTC present with anterior 
neck pain than do patients with PTC and that patients with MTC and neck pain have an in-
creased risk of LN metastases. The results of this study suggest that MTC patients, who 
present with concomitant neck pain, should undergo a total thyroidectomy, prophylactic 
bilateral central neck dissection, and ipsilateral lateral neck dissection. 
Key words: Medullary thyroid cancer, lymph node, papillary thyroid cancer  
Introduction 
Medullary thyroid cancer (MTC), which behaves 
more  aggressively  than  well-differentiated  thyroid 
cancer (WDTC) of follicular cell origin, accounts for 
13%  of  all  thyroid-related  deaths.[1]  Most  cases  of 
MTC arise sporadically, but about 25% are hereditary, 
as part of multiple endocrine neoplasia type 2 (MEN 
2a  and  2b)  and  isolated  familial  MTC  (FMTC). 
Though  both  forms  (i.e.,  sporadic  and  inherited)  of 
MTC  have  a  propensity  for  lymphatic  and  distant 
metastases,[2] the inherited form develops at an ear-
lier age, is associated with C-cell hyperplasia, and is 
often  multifocal.  The  differences  in  aggressive  be-Journal of Cancer 2011, 2 
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havior correlate with specific mutations in the rear-
ranged  during  transfection  (RET)  protooncogene, 
mutations that are present in nearly all patients with 
inherited MTC. Similar somatic mutations are found 
in about 25% of patients with sporadic MTC.[3] The 
overall 10-year survival rate of patients with MTC is 
about 75%, as compared with over 90% for patients 
with WDTC.[4-6] 
Lymph node (LN) metastases are more common 
in patients with larger tumors, with specific RET mu-
tations,  and  with  markedly  elevated  calcitonin  and 
carcinoembryonic antigen levels.[4] Clinical parame-
ters  also  dictate  the  extent  of  disease;  for  example, 
palpable lateral LNs in patients with proven MTC are 
highly  predictive  of  LN  metastases.  Other  clinical 
features  that  suggest  extensive  disease  include 
symptoms  of  dysphagia,  dyspnea,  and  hoarse-
ness.[7,8] As such, the American Thyroid Association 
(ATA)  recommends  that  all  patients  with  sporadic 
MTC undergo a prophylactic central neck dissection 
during the initial total thyroidectomy.[5] However, a 
recent study reports that numerous surgeons are not 
following  the  new  ATA  guidelines.[9]  Therefore,  in 
order to support the recommendations for a central 
neck dissection in patients with MTC we sought to 
determine if a clinical parameter can predict the ex-
tent of disease in MTC.  
It is intuitive to infer that anterior neck pain in 
patients with a palpable neck mass is associated with 
more extensive disease, but we sought  to answer 2 
questions,  in  particular,  in  our  study:  (a)  Can  the 
symptom of anterior neck pain predict the extent of 
disease in patients with no gross clinical features of 
thyroid cancer? (b) Are patients who complain of an-
terior neck pain and are found to have a thyroid nod-
ule more likely to have MTC? Thus, the goals of our 
study were to determine whether or not the symptom 
of  anterior  neck  pain  occurred  more  frequently  in 
patients  with  MTC  than  papillary  thyroid  cancer 
(PTC) and whether or not it predicted the clinical and 
pathologic extent of disease in patients with MTC. 
Materials and Methods 
We  retrospectively  analyzed  the  records  of  all 
patients who underwent a neck operation for MTC at 
the  University  of  California,  San  Francisco,  from 
February 1998 through December 2008. We defined a 
neck operation as a thyroidectomy alone, a thyroid-
ectomy with central LN dissection, or a thyroidecto-
my with central and either ipsilateral or bilateral lat-
eral LN dissection. We recorded patient characteris-
tics, family history, preoperative ultrasound results, 
operative results, and pathology data. In addition, at 
the  time  of  the  initial  preoperative  encounter,  each 
patient had prospectively completed a questionnaire 
addressing his or her presenting symptoms (e.g., neck 
pain,  hoarseness,  dysphagia,  dyspnea).  Neck  pain 
was defined as any subjective complaint of anterior 
neck discomfort, ache, pressure, or sharp, throbbing, 
or dull sensations in the region of the thyroid gland, 
with or without palpation. 
The inclusion criteria for our study included the 
diagnosis  of  newly  diagnosed  MTC  (sporadic  and 
inherited).  We  excluded  patients  who  did  not  have 
documentation  on  the  presence  or  absence  of  neck 
pain, either on the clinic evaluation or the question-
naire.  Our  control  group  consisted  of  randomly  se-
lected patients with PTC who underwent a thyroid-
ectomy, with or without  LN dissection during. The 
number of randomly selected PTC patients equaled 
the final number of patients in the MTC study group. 
The same exclusion criteria used for our study group 
was followed. The institutional review board at the 
University of California, San Francisco, approved the 
study.  
We compared the presence or absence of neck 
pain with the clinical and pathologic extent of disease 
in patients with MTC and PTC. We defined the clini-
cal extent of disease by the presence of palpable or 
ultrasound-proven LN metastasis and/or by evidence 
of wide metastatic disease. We also evaluated the ex-
tent of disease per the patient’s final pathology test 
results, looking at capsular invasion, lymphatic inva-
sion, vascular invasion, and LN involvement. 
Data are reported as the mean ± standard devia-
tion  (SD)  or  as  numbers  (percent).  To  compare  the 
symptom of pain and the extent of disease, we used 
the Fisher's exact test; to compare nonparametric data, 
the Mann-Whitney test. For each variable, we calcu-
lated a 2-tailed p-value. We considered a p-value < 
0.05 to be statistically significant. 
Results 
During our 130-month study period, 109 patients 
with MTC underwent a neck operation at our institu-
tion; 50 (46%) met our inclusion criteria for evalua-
tion.  Our  control  group  consisted  of  50  randomly 
chosen patients who underwent a neck operation for 
PTC. We found no significant difference in age or race 
between patients the MTC and PTC patients, but there 
was  a  significant  gender  difference  between  both 
groups.  Although  women  made  up  the  majority  of 
patients in both groups, there were disproportionally 
more women in the PTC  control group than in  the 
MTC  study  group  (Table  1).  Most  patients  in  both 
groups  were  asymptomatic,  but  22%  of  those  with 
MTC had neck pain at presentation, as compared with 
only 6% of those with PTC (p = 0.041). Only patients Journal of Cancer 2011, 2 
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with MTC (2 of 50) had hoarseness; however, the dif-
ference between the 2 groups regarding this symptom 
was not statistically significant.  
The final pathology test results regarding mul-
tifocality,  capsular  invasion,  and  vascular  invasion 
did  not  significantly  differ  between  the  2  groups. 
However, patients with MTC had a higher rate (20%) 
of lymphatic invasion than those with PTC (2%); this 
difference  was  significant  (p  =  0.008).  Despite  this 
increased risk of lymphatic invasion for MTC patients, 
their incidence of LN metastases was not higher than 
the incidence for PTC patients (Table 1). 
The stage of disease at presentation significantly 
differed  between  the  2  groups.  Patients  with  MTC 
presented  less  often  with  stage  I  disease  (32%),  as 
compared with patients with PTC (72%) (p = 0.0001). 
Conversely, patients with MTC presented more often 
with  stage  IV  disease  (30%),  as  compared  with  pa-
tients with PTC (2%) (p = 0.0001). We found no dif-
ference between the 2 groups in terms of stage II and 
stage III at presentation. 
Of the 50 patients with MTC, 11 (22%) had neck 
pain. Neck pain was distributed in the region of the 
thyroid  gland,  and  no  patient  presented  with  neck 
pain  from  palpable  lymphadenopathy.  No  patient 
with  MTC  presented  with  clinically  palpable  lym-
phadenopathy. Patients with (vs. without) neck pain 
tended to be older, but, the difference was not statis-
tically  significant  (Table  2).  We  found  no  statistical 
differences  in  gender  and  family  history  (inherited 
MTC, sporadic MTC, and sporadic MTC with somatic 
mutations) between the 2 groups. Similarly, we found 
no  difference  in  preoperative  ultrasound-proven 
lymphadenopathy between the 2 groups (Table 2).  
 
Table 1. Patients with medullary thyroid cancer (MTC) vs. papillary thyroid cancer (PTC) 
  MTC  PTC  p-value 
Total number of patients, n  50  50   
Age (years), mean ± SD  43.0 ± 18.2  49.9 ± 16.3  0.089 
Gender, n (%)       
 Female  30 (60)   43 (86)    
 Male  20 (40)  7 (14)  0.006 
Race, n (%)       
 White   34 (68)   29 (58)   0.408 
 Asian  5 (10)   11 (22)   0.171 
 African American  2 (4)   1 (2)   1.000 
 Latino  2 (4)   1 (2)   1.000 
 Other  7 (14)   8 (16)   1.000 
Symptoms, n (%)       
 Asymptomatic  37 (74)  47 (94)  0.012 
 Neck pain  11 (22)  3 (6)  0.041 
 Hoarseness  2 (4)  0  0.495 
Pathologic findings, n (%)       
 Multifocal  26 (52)  27 (54)  1.000 
 Capsular invasion  9 (18)  9 (18)  1.000 
 Vascular invasion  5 (10)  2 (4)  0.437 
 Lymphatic invasion  10 (20)  1 (2)  0.008 
 Lymph node (LN) metastases  23 (46)  14 (28)  0.09 
Stage of disease, n (%)       
 Stage I  16 (32)  36 (72)  0.0001 
 Stage II  9 (18)  9 (18)  1.000 
 Stage III  7 (14)  4 (8)  0.525 
 Stage IVa  11 (22)  1 (2)  0.004 
 Stage IVb  0  0  1.000 
 Stage IVc  4 (8)  0  0.117 
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Table 2. Patients with medullary thyroid cancer (MTC), with and without neck pain at presentation 
Medullary thyroid cancer (MTC)  Pain  No pain  p-value 
Total number of patients, n  11  39   
Age (years), mean ± SD  51.6 ± 11.5  40.6 ± 19.1  0.073 
Gender, n (%)       
 Female    7 (64)   23 (59)    
 Male   4 (36)  16 (41)  1.000 
Family history of MTC, n (%)   2 (18)  15 (38)  1.000 
Ultrasound-proven nodal disease, n (%)  2 (18)  6 (15)  1.000 
Histologic findings, n (%)       
 Tumor diameter (cm), mean ± SD   2.2 ± 1.4   1.8 ± 1.4   0.340 
 Multifocal  4 (36)   22 (56)   0.314 
 Capsular invasion  2 (18)  7 (18)  1.000 
 Vascular invasion  2 (18)  3 (8)  0.301 
 Lymphatic invasion  1 (9)  9 (23)  0.424 
 Lymph node (LN) metastases  9 (82)  14 (36)  0.014 
Stage of disease, n (%)       
 Stage I  2 (18)   14 (36)   0.466 
 Stage II  0   9 (23)  0.178 
 Stage III  2 (18)  5 (13)  0.641 
 Stage IVa  5 (45)  6 (15)  0.048 
 Stage IVb  0   0   1.000 
 Stage IVc  2 (18)  2 (5)  0.206 
 Stages I-II, grouped together  2 (18)  23 (64)   
 Stages III-IV, grouped together  9 (82)  13 (36)  0.014 
 
Table 3. Patients with papillary thyroid cancer (PTC), with and without neck pain at presentation  
Papillary thyroid cancer (PTC)  Pain  No pain  p-value 
Total number of patients, n  3  47   
Age (years), mean ± SD  73.7 ± 9.9  48.4 ± 15.4  0.019 
Gender, n (%)       
 Female   3 (100)   40 (85)    
 Male   0  7 (15)  1.000 
Family history of PTC   0  2 (4)  1.000 
Histologic findings, n (%)       
 Tumor diameter (cm), mean ± SD   1.1 ± 1.2   1.6 ± 1.7   0.347 
 Multifocal  2 (67)  25 (53)  1.000 
 Capsular invasion  1 (33)  8 (17)  0.456 
 Vascular invasion  0  2 (4)  1.000 
 Lymphatic invasion  0  1 (2)  1.000 
 Lymph node (LN) metastases  1 (33)  13 (28)  1.000 
Stage of disease, n (%)       
 Stage I  2 (67)   34 (72)  1.000 
 Stage II  1 (33)  8 (17)  0.456 
 Stage III    4 (9)  1.000 
 Stage IVa    1 (2)  1.000 
 Stage IVb       
 Stage IVc       
 Stages I-II, grouped together  3 (100)  42 (89)   
 Stages III-IV, grouped together    5 (11)  1.000 
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No histologic differences per the final pathology 
test results were apparent between the 2 groups; the 
rate of multifocality, capsular invasion, vascular in-
vasion, and lymphatic invasion were similar (Table 2). 
However, patients with neck pain were more likely to 
have LN metastases (82%) than  those  without neck 
pain (36%); of which 7 of 9 (78%) patients with neck 
pain compared to 7 of 14 (50%) without neck pain had 
both central and ipsilateral lateral neck LN metasta-
ses. This difference was statistically significant (p = 
0.014) and translated into a higher stage of disease. Of 
patients with neck pain, only 18% had either stage I or 
II disease, as compared with 64% without neck pain; 
however, 82% of patients with neck pain had stage III 
or  IV  disease,  as  compared  with  only  36%  without 
pain (p = 0.014). In 3 patients without neck pain, we 
could not definitively determine the stage of disease. 
Unlike in our MTC study group, the age of pa-
tients with vs. without neck pain differed in our PTC 
control group. Patients with PTC with (vs. without) 
neck  pain  were  older  (median  age,  73.7  years  with 
neck pain vs. 48.4 without, p = 0.019). As in our MTC 
study group, we found no difference in gender, ge-
netic makeup, or histologic findings in our PTC con-
trol group (Table 3). We also found no difference in 
our PTC control group in the incidence of LN metas-
tases between patients with vs. without neck pain, nor 
did  the  stage  of  disease  differ  in  any  way  between 
those 2 subgroups of patients with PTC (Table 3). 
Discussion 
MTC, an aggressive cancer, is associated with a 
worse  prognosis  than  WDTC  of  follicular  cell 
origin.[5] In patients with MTC, the high incidence of 
LN metastases increases the risk of developing dis-
seminated disease and contributes to their decreased 
survival rate. A cure can be achieved in most patients 
with MTC who do not have LN metastases, but the 
presence of LN metastases adversely affects the pos-
sibility of a biochemical cure and of survival.[6] Mul-
tifocal disease is associated with an increased risk of 
capsular and extrathyroidal invasion; the presence of 
LN metastases in patients with MTC and in patients 
with PTC portends a worse prognosis. Additionally, 
in both groups, multifocality is a predictor of LN me-
tastases.[10]  The  presence  of  central  LN  metastases 
also increases the risk of lateral LN involvement.[11] 
Despite our knowledge of histologic indicators 
of LN metastases, no good clinical predictors of LN 
metastases exist. In our study, we set out to determine 
(a) whether or not anterior neck pain at presentation 
was more common in patients with MTC than in those 
with PTC and (b) whether or not neck pain predicted 
LN metastases.  
We  found  no  statistical  difference  in  the  inci-
dence of LN metastases between patients with MTC 
and patients with PTC (Table 1). However, patients 
with MTC had significantly more anterior neck pain, 
as  compared  with  patients  with  patients  with  PTC. 
Moreover, patients with MTC with neck pain had a 
significantly higher risk of having LN metastases, as 
compared with their fellow patients with MTC with-
out neck pain. This difference also translated into a 
higher rate of concurrent central and ipsilateral lateral 
LN metastases in our MTC pain group, compared to 
MTC patients without pain. But in our control group 
of patients with PTC, we found no significant differ-
ence between those with and without neck pain. The 
difference in the incidence of LN metastases between 
MTC patients with and without neck pain reflects the 
higher stage of disease in those with neck pain (82% at 
stage III to IV), as compared with those without neck 
pain (36% at stages III to IV). This difference in the 
stage of disease was not apparent in our control group 
of patients with PTC (Table 3). 
Our study has several limitations. First, although 
symptoms were documented prospectively, this is a 
retrospective analysis, which may have resulted in a 
selection bias in favor of patients with neck pain. Se-
cond, although we attempted to normalize our data 
by including a control group of an equal number of 
patients with PTC, our study group and our control 
group were not matched for the stage of disease. More 
patients with stage III or IV disease were in our study 
group  (patients  with  MTC),  as  compared  with  our 
control  group  (patients  with  PTC).  Although  we 
found  a  statistically  significant  difference  in  the 
number  of  patients  with  anterior  neck  pain  in  our 
study  (MTC)  group,  as  compared  with  our  control 
(PTC)  group,  this  difference  may  simply  reflect  the 
larger number of patients with stage III or IV disease 
in our study (MTC) group – although we feel that is 
unlikely, because several patients had painful thyroid 
nodules for several years before treatment. Third, the 
small sample size of both our study group and our 
control group may not have ensured adequate repre-
sentation  of  the  general  population.  However,  this 
limitation is a reflection of the rarity of MTC and the 
difficulty in obtaining a larger series at a single insti-
tution.  Forth,  although  we  found  no  difference  in 
presentation  between  sporadic  and  inherited  MTC, 
the small number of patients with inherited MTC may 
not have allowed adequate assessment. Lastly, since 
our institution is a tertiary referral hospital, we were 
unable to obtain all the calcitonin and CEA levels at 
the initial diagnosis of each patient. This limited our 
ability  to  correlate  the  biochemical  levels  with  the 
symptom of anterior neck pain.  Journal of Cancer 2011, 2 
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In summary, the results of our study suggest that 
more patients with MTC present with anterior neck 
pain than do patients with PTC and that those with 
MTC have an increased risk of LN metastases (despite 
having  no  physical  or  ultrasound  evidence  of  LN 
metastases),  as  compared  with  patients  with  PTC. 
Most clinicians agree that MTC is an aggressive dis-
ease  and  therefore  a  bilateral  prophylactic  central 
neck dissection should be performed at the time of 
total  thyroidectomy  according  to  the  ATA  guide-
lines.[5] However, reservations may exist about per-
forming a bilateral central neck dissection in patients 
with sporadic MTC. This study confirms the aggres-
sive nature of MTC, especially in patients who present 
with concomitant anterior neck pain. The results of 
this  retrospective  analysis  support  the  ATA  guide-
lines recommendation to perform a prophylactic cen-
tral  lymph  node  dissection  in  patients  with  MTC. 
Furthermore, our study suggests that MTC patients 
presenting with anterior neck pain should undergo a 
simultaneous ipsilateral lateral neck dissection at the 
initial operation. However, future prospective studies 
are needed to verify and support our findings. 
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